Related Experiment Videos
Metabolic polymorphism of E6123 in rhesus monkey
Summary
Metabolic differences in rhesus monkeys affect how the drug E6123 is processed. Poor metabolizers show higher drug levels and altered excretion, suggesting enzyme variations influence drug metabolism.
Area of Science:
- Pharmacology
- Drug Metabolism
- Biochemistry
Background:
- Platelet activating factor receptor antagonists are crucial in treating inflammatory conditions.
- Understanding drug metabolism is essential for optimizing therapeutic efficacy and safety.
- E6123 is a novel thienodiazepine derivative with potential therapeutic applications.
Purpose of the Study:
- To investigate the in vivo and in vitro metabolic polymorphism of E6123 in rhesus monkeys.
- To identify the specific metabolic pathways and enzymes responsible for E6123 metabolism.
- To elucidate the pharmacokinetic differences between poor metabolizers (PMs) and extensive metabolizers (EMs) of E6123.
Main Methods:
- Administered radiolabeled 14C-E6123 intravenously to rhesus monkeys.
- Quantified radioactivity in blood, plasma, and red blood cells over 24 hours.
- Analyzed radioactivity excretion in urine and feces.
- Conducted in vitro studies to identify metabolic enzymes and pathways.
Main Results:
- Radioactivity levels were 1.3-1.5 times higher in PMs compared to EMs.
- EMs primarily excreted radioactivity in urine, while PMs showed equal excretion in urine and feces.
- Metabolic polymorphism is attributed to differences in the hydrolysis of an amide side chain.
- EMs appear to possess both high and low affinity enzymes, whereas PMs possess only one type.
Conclusions:
- Rhesus monkeys exhibit metabolic polymorphism for E6123, impacting drug disposition.
- The observed differences are linked to variations in amide side chain hydrolysis.
- The presence or absence of a high-affinity enzyme likely dictates the metabolic phenotype, influencing E6123 pharmacokinetics.